Business Context and Reporting Period
This Form 6-K filing by GSK plc, a global biopharma company, covers the month of April 2026. The report was issued on April 1, 2026, from London, UK, to comply with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R regarding voting rights.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and share capital structure.
| Metric | Value |
|---|---|
| Issued Share Capital (as of March 31, 2026) | 4,316,179,781 Ordinary Shares (31 pence each) |
| Treasury Shares | 256,112,615 |
| Total Voting Rights | 4,060,067,166 |
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It serves as a notification of the current share capital and voting rights count as of March 31, 2026.
Guidance, Outlook, and Risks
The document contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a regulatory notification intended to assist shareholders in calculating their interest thresholds under FCA rules.
Key Facts for Investor Verification
- Voting Rights Denominator: Shareholders should use 4,060,067,166 as the total number of voting rights to determine notification requirements under FCA rules.
- Treasury Holdings: Approximately 256 million shares are held in treasury and do not carry voting rights.
- Share Price: The nominal value of each Ordinary Share is 31 pence.
- Contact for Notifications: Shareholders may send notifications to company.secretary@gsk.com.